NCT04186013 - Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 18, 2019

Primary Completion Date

February 28, 2027

Study Completion Date

May 31, 2027

Conditions

Bladder Cancer

Interventions

DRUG

Atezolizumab Injection [Tecentriq]

intravenous infusion of 1.200 mg of Atezolizumab administered intravenously every 3 weeks for a total of 6 doses

RADIATION

External Beam Radiation Therapy (EBRT)

60 Gy of radiotherapy in 30 fractions overs 6 weeks at 2 Gy/day

Trial Locations (10)

6015

Hospital Arnau de Vilanova, Valencia

18016

Hospital Clínico Universitario San Cecilio, Granada

27003

Hospital Universitario Lucus Augusti, Lugo

28006

Hospital Universitario La Princesa, Madrid

28050

Hospital HM Sanchinarro, Madrid

32005

Complejo Hospitalario Universitario Ourense, Ourense

33011

Hospital Universitario Central de Asturias, Oviedo

43204

Hospital Universitario Sant Joan de Reus, Reus

08243

Althaia Xarxa Assintencial, Manresa

08208

Consorci Corporació Sanitària Parc Taulí, Sabadell

All Listed Sponsors

collaborator

Roche Farma, S.A

INDUSTRY

collaborator

Dynamic Science S.L.

INDUSTRY

lead

Spanish Oncology Genito-Urinary Group

OTHER